



A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and Wales

July 17, 2024

After the approval of the first bispecific antibody for multiple myeloma last month, the National Institute for Health and Care Excellence (NICE, the United Kingdom's public body for medicine appraisals) approved today, 16 July 2024, a second bispecific drug, teclistamab

After the [approval of the first bispecific antibody for multiple myeloma](#) last month, the National Institute for Health and Care Excellence (NICE, the United Kingdom's public body for medicine appraisals) approved today, 16 July 2024, a second bispecific drug, teclistamab. Commercially known as Tecvayli® and marketed by Janssen, the drug has been approved for people at fourth line and beyond, with a few further restrictions.

Please click [here](#) to read more about this approval in England and Wales and the efforts of Myeloma UK to push for wider patient access.

To find out more about teclistamab please see MPE's factsheet on this drug [here](#).